Effect and mechanism of resveratrol alleviates hepatic ischemia reperfusion injury by HMGB1 in rats

Abstract

Abstract:

AIM: To investigate the effect and mechanism of resveratrol on the expression of high mobility group box 1 in rats with hepatic ischemia-reperfusion injury. METHODS: Thirty healthy male Sprague-Dawley (SD) rats were randomly divided into three groups: sham control (SC) group, hepatic ischemia reperfusion injury (HIR) group and resveratrol (Res) group. The blood samples and liver tissue samples were collected. The pathological changes of the liver were observed. Serum ALT, AST and AKP activity were detected as indicators of liver function damage and the content of TNF-α and IL-6 in serum were detected by ELISA. The expressions of HMGBl and TLR4 protein and mRNA were determined by Western Blot and RT-PCR.RESULTS:Compared with the HIR group, the pathological injury of the liver was significantly improved and the concentrations of serum AST, ALT and AKP were significantly lower in Res group (P<0.01); meanwhile, the expression of HMGB1 and TLR4 protein and mRNA of hepatic tissue were decreased, serum inflammatory factors IL-6 and TNF-α were also significantly decreased (P<0.01). CONCLUSION: Resveratrol shows significant protective effect on hepatic ischemia reperfusion injury in rat. This may be related with inhibiting the HMGBl-TLR4 signaling pathway and alleviating the inflammatory response.

Key words: hepatic ischemia reperfusion injury, high mobility group box 1, Toll-like receptor 4, resveratrol, inflammatory cytokine

CLC Number:

R965.2

SONG Juan, TIAN Xiaoxia, LI Baohong, WANG Dong, MENG Dongchao, LU Yanzhen. Effect and mechanism of resveratrol alleviates hepatic ischemia reperfusion injury by HMGB1 in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1215-1220.

References

［1］Elias-Miró M，Jiménez-Castro MB，Rodés J，et al. Current knowledge on oxidative stress in hepatic ischemia/reperfusion［J］．Free Radic Res，2013，47(8)：555-568.
［2］王清卿，赵鑫，陈玉超，等．肝脏缺血再灌注损伤机制及干预的研究进展［J］．临床肝胆病杂志，2016，32(6)：1225-1229.
［3］Tsung A，Sahai R，Tanaka H，et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion［J］．J Exp Med，2005，201(7)：1135-1143.
［4］Ilmakunnas M，Tukiainen EM，Rouhiainen A，et al．High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation［J］．Liver Transpl，2008，14(10)：1517-1525.
［5］Cardinal J，Pan P，Dhupar R，et al．Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury［J］．Hepatology，2009，50(2)：565-574.
［6］Ogiku M，Kono H，Hara M，et al．Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats［J］．J Pharmacol Exp Ther，2011，339(1)：93-98.
［7］Yamamoto T，Ono T，Ito T，et al．Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats［J］．Crit Care Med，2010，38(3)：879-885.
［8］宋娟，郭雅玲，任广宗，等．白藜芦醇对大鼠肝脏缺血再灌注损伤的保护作用及机制研究［J］．长治医学院学报，2015，29(3)：170-173.
［9］Vitali R，Palone F，Pierdomenico M，et al. Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation［J］．Biochem Pharmacol， 2015，97(3): 292-299.
［10］Sims GP，Rowe DC，Rietdijk ST，et al. HMGB1 and RAGE in inflammation and cancer［J］．Annu Rev Immunol，2010，28：367-388.
［11］Hataji K，Watanabe T，Oowada S，et al．Effects of a calcium-channel blocker (CV159) on hepatic ischemia/reperfusion injury in rats: evaluation with selective NO/pO2 electrodes and an electron paramagnetic resonance spin-trapping method［J］．Biol Pharm Bull，2010，33(1): 77-83.
［12］Park JS，Gamboni-Robertson F，He Q，et al．High mobility group box 1 protein interacts with multiple Toll-like receptors［J］．Am J Physiol Cell Physiol，2006，290(3)：C917-C924.
［13］Park JS，Svetkauskaite D，He Q，et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein［J］. J Biol Chem，2004，279(9): 7370-7377.
［14］Doi K，Ishizu T，Tsukamoto-Sumida M，et al．The high-mobility group protein B1-Toll-like receptor 4 pathway contributes to the acute lung injury induced by bilateral nephrectomy ［J］．Kidney Int，2014，86(2)：316-326.
［15］Mcdonald KA，Huang H，Tohme S，et al. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling ［J］. Mol Med，2015，20: 639-648.
［16］Vardanian AJ，Busuttil RW，Kupiec-Weglinski JW．Molecular mediators of liver ischemia and reperfusion injury：a brief review［J］．Mol Med，2008，14(5/6)：337-345.
［17］Yang H，Hreggvidsdottir HS，Palmblad K，et al．A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release［J］．Proc Natl Acad Sci U S A，2010，107(26)：11942-11947.
［18］Qing YF，Zhang QB，Zhou JG，et al. Changes in toll-like receptor(TLR)4-NFκB-IL1β signaling in male gout patients might be involved in the pathogenesis of primary gouty arthritis［J］. Rheumatol Int，2014，34(2)：213-220.

[1]	GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465.
[2]	WANG Yaya, CHU Zixuan, YANG Junling, Olajide E. Olaleye, HE Rongrong, LI Muzi, CHENG Chen, LI Chuan. Potential health benefits of resveratrol: a pharmacokinetics-caused conundrum [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 931-954.
[3]	XU Tiantian, WU Xiangyao, PI Aiwen, CHAI Hui, ZHANG Bin, WANG Bangcai, DOU Xiaobing, ZHU Linwensi. Salvianolic acid A improves palmitie acid-induced lipotoxicity in cardiomyocyte via inhibiting TLR4/JNK MAPK [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 121-128.
[4]	DENG Li, TIAN Jing. Resveratrol suppresses NLRP3 inflammasome activation in colonic epithelial cells triggered by Escherichia coli O104∶H4 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 167-173.
[5]	WU Yi, ZHU Akao, SHAN Yuqiang, YING Rongchao, JIN Huicheng. Resveratrol regulates miR-409-3p/FKBP14 to inhibit the malignant biological processes of gastric cancer BGC823 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 968-975.
[6]	YUAN Lijialong, YUAN Ronghui, WANG Jin, DENG Ziwei, WANG Hongqiang, DENG Ye, GONG Lu, JIN Yuanxiang, SHI Zhihua. Effects of resveratrol on autophagy of tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1066-1073.
[7]	JIANG Weiyu, HU Xudong, CHEN Yunlin, RUAN Chaoyue, XU Nanjian, WANG Yang, XU Dingli, ZHANG Jiaming, LI Haojie, MA Weihu. Esveratrol inhibits NLRP3 inflammasome activation in rabbits with spinal cord injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 850-856.
[8]	WU Qiaoyu, YUAN Hong, LU Yao. Evaluation of the effects of resveratrol on the activity human cytochrome P450 through combined probe method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 426-432.
[9]	ZHOU Haiyan, WANG Kailing . Resveratrol protects human retinal pigment epithelial cells from toxicity of high glucose by up-regulation of miR-26a [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 285-292.
[10]	SONG Hui, WANG Yinghao. Resveratrol inhibits the proliferation of retinoblastoma cells via miR-937/FOXQ1 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 174-181.
[11]	LI Min, WANG Shanshan, LIU Zhonghe, JIANG Deguo. Expression and mechanism of p38MAPK signaling pathway in chronic pulpitis rats with pain [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 644-649.
[12]	HUANG Lijia, HUANG Yang, KONG Jinsong, ZHENG Xin, GONG Xiaokang, RUAN Jianwei, WANG Haibao. Inhibition of articular cartilage degeneration by atorvastatin calcium via STAT1-caspase-3 signaling axis in rats with knee osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 743-748.
[13]	WANG Xianhai, LI Zhenbin, LI Xiaomei, ZHANG Jianguo, SHI Xinmin, XU Haiyan, FENG Minlu, SHI Mengqiong . Study of Tongjing dingyunwan blocking NF-κB activation on the MCP-1/CCR2 signaling pathway and expressions of TNF-α, IL-1β, IL-6 in the cervical spondylosis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 370-376.
[14]	ZHOU Xiahui, WANG Qinglai, ZHU Xuemei, PAN Rongrong, PAN Shenglian, ZHU Fanghui, WANG Ding, LUO Xiaohong. Effects of angelica sinensis polysaccharide on TLR4/MyD88/NF-κB pathway in rats with diabetic neuropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1340-1347.
[15]	LI Fang, ZHENG Liupu, WENG Jianlong, GUO Tao, SONG Xingwei, ZHENG Rongyuan. Therapeutic time window of effectiveness for idazoxan ameliorating brain damage of rats with experimental autoimmune encephalomyelitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 1-7.